Brief: Lumos Pharma Announces Encouraging Interim Mid-stage Study Results For Pediatric Growth Drug

Lumos Pharma

14/11/2022 11:13

Nov 14 (Reuters) - Lumos Pharma Inc  LUMO.O :
    * LUMOS PHARMA ANNOUNCES ENCOURAGING INTERIM RESULTS FROM
TWO
PHASE 2 TRIALS EVALUATING ORAL LUM-201 FOR MODERATE PEDIATRIC
GROWTH HORMONE DEFICIENCY
    * LUMOS PHARMA INC - LUM-201 MET EXPECTATIONS IN INTERIM
ANALYSIS
OF TWO PHASE 2 TRIALS EVALUATING GROWTH IN PEDIATRIC GROWTH
HORMONE DEFICIENCY (PGHD)
    * LUMOS PHARMA - INTERIM RESULTS FOR ABOUT 50% ENROLLMENT OF
ORAGROWTH210 TRIAL SHOWED MEAN AHV OF 8.6 CM AT SIX MONTHS FOR
1.6 MG/KG/DAY LUM-201
    * LUMOS PHARMA INC - DATA FURTHER DE-RISK CLINICAL PROGRAM
AND
SUPPORT SELECTION OF 1.6 MG/KG/DAY LUM-201 DOSE FOR PIVOTAL
PHASE 3 TRIAL
    * LUMOS PHARMA INC - CONTINUES TO ANTICIPATE PRIMARY OUTCOME
READOUT WITH ALL 80 SUBJECTS AT SIX MONTHS IN 2H 2023 FROM
ORAGROWTH210 TRIAL

Source text for Eikon:  ID:nGNX8S8FZT 
Further company coverage:  LUMO.O 
 ((Reuters.Briefs@thomsonreuters.com;))